| Zhang, Guohui |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
| Zhu, Yan |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
| Completed | 3 | 257 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 07/24 | 07/24 | | |
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee |
|
|
| Active, not recruiting | 3 | 405 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteo Arthritis Knee | 02/26 | 03/26 | | |
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight |
|
|
| Active, not recruiting | 3 | 1000 | Europe, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea | 05/26 | 05/26 | | |
NCT04181489: Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS |
|
|
| Recruiting | 2 | 55 | RoW | Sintilimab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone | The First Affiliated Hospital with Nanjing Medical University | EBV-Positive DLBCL, Nos | 12/23 | 12/23 | | |
| Qian, Jun |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
NCT05840341: Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer |
|
|
| Recruiting | 3 | 306 | RoW | QingyiHuaji optimized formula, standard chemotherapy | Fudan University | Pancreatic Neoplasms | 12/25 | 12/25 | | |
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 254 | RoW | SPH4336 Tablets, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 03/25 | 08/25 | | |
NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 115 | RoW | VC004 | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 01/24 | 06/24 | | |
NCT04689100: Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 259 | RoW | JMT101, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan; | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumor | 12/21 | 06/22 | | |
NCT05968001: Obinutuzumab in Chinese Real-world Patients With iNHL |
|
|
| Not yet recruiting | N/A | 400 | RoW | Obinutuzumab | Affiliated Hospital of Nantong University | Lymphomas Non-Hodgkin's B-Cell | 12/24 | 07/26 | | |
| Shan, Xiuhong |
NCT05722275: Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics |
|
|
| Recruiting | N/A | 400 | Europe, RoW | Peritoneal metastasis status ascertainment | Chinese Academy of Sciences, Peking University Cancer Hospital & Institute, Zhenjiang First People's Hospital, The First Affiliated Hospital of Zhengzhou University, Nanfang Hospital of Southern Medical University, Guizhou Provincial People's Hospital, Henan Cancer Hospital, Yunnan Cancer Hospital, Guangdong Provincial People's Hospital, Guangzhou Medical University, Fujian Medical University Union Hospital, Shanxi Province Cancer Hospital, Sun Yat-sen University, Beihang University, Scientific Institute San Raffaele | Gastric Cancer, Peritoneal Metastases | 12/23 | 12/28 | | |
NCT06035250: AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy |
|
|
| Recruiting | N/A | 200 | Europe, RoW | Neoadjuvant Chemotherapy | Chinese Academy of Sciences, Peking University Cancer Hospital & Institute, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Yunnan Cancer Hospital, Henan Cancer Hospital, Zhenjiang First People's Hospital, First Hospital of China Medical University, Cancer Hospital of Guangxi Medical University, Peking University People's Hospital, Tianjin Medical University Cancer Institute and Hospital, The First Affiliated Hospital of Zhengzhou University, Nanfang Hospital, Southern Medical University, The Affiliated Hospital of Qingdao University, Ruijin Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Peking Union Medical College Hospital, Xiangya Hospital of Central South University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The First Affiliated Hospital of Soochow University, First Affiliated Hospital, Sun Yat-Sen University, Fujian Medical University Union Hospital, Fujian Cancer Hospital, San Raffaele University Hospital, Italy | Gastric Cancer, Image, Pathology | 08/24 | 12/29 | | |
| Xie, Yong |
OPTIMA-6, NCT05410925: Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction |
|
|
| Recruiting | 4 | 2260 | RoW | Recombinant staphylokinase, Placebo | The First Affiliated Hospital with Nanjing Medical University | ST Elevation Myocardial Infarction | 12/26 | 12/27 | | |
NCT06729385: Blood Proteome Profiling Identifies Biomarkers in Ischemic Stroke |
|
|
| Recruiting | N/A | 80 | RoW | The blood Proteome Profiling | Capital Medical University | Stroke | 06/25 | 08/25 | | |
NCT05410652: Helicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method) |
|
|
| Completed | N/A | 1176 | RoW | Detection of fecal samples with diagnostic kit, Sanger Sequencing group, Bacterial culture and drug sensitivity test of gastric mucosa samples | Nanjing First Hospital, Nanjing Medical University | Helicobacter Pylori Infection, Helicobacter Pylori gyrA Levofloxacin Resistance Mutation, Fecal Drug Resistance Gene Detection, Helicobacter Pylori Infection, Susceptibility to | 09/23 | 10/23 | | |
